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The epidermal-derived “alarmins” high-mobility group 
box 1 (HMGB1) protein and interleukin-33 (IL-33) are 
upregulated in patients with atopic dermatitis. How-
ever, their capacity as pro-inflammatory cytokines and 
their derived effects on skin barrier regulation are po-
orly elucidated. We investigated the impact of HMGB1 
and IL-33 on gene transcription, protein expression and 
epidermal differentiation across 3 distinct keratinocyte 
in vitro models. Primary keratinocytes from healthy 
donors were used in submerged monolayer cultures, 
3D human epidermis equivalents and 3D human skin 
equivalents. All keratinocyte models underwent 96-h 
stimulation with HMGB1 (100 μM) or IL-33 (100 ng/
ml) using IL-4 (50 ng/ml) as positive control of regu-
lation and vehicle as negative control. We found that 
HMGB1 and IL-33 downregulated transcription of seve-
ral genes from members of the epidermal differentia-
tion complex, including filaggrin. Furthermore, HMGB1 
downregulated the expression of the encoded proteins 
in the upper epidermis. Finally, IL-33 and HMGB1 ul-
timately led to impaired epidermal growth and matura-
tion. In conclusion, HMGB1 and IL-33 could play a sig-
nificant role in the atopic dermatitis pathophysiology 
due to negative regulation of structural proteins, stra-
tum corneum formation and epidermal growth.
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The skin is a vital first line of defence between the environment and the human body. Studies indicate 
that defects in epidermal barrier function contribute to 
triggering and perpetuating skin inflammation in atopic 
dermatitis (AD) (1–5). Furthermore, disease activity 
and barrier function seem to be intimately related, and 
fluctuations in either can drive the disease (6). The role 
of skin barrier dysfunction as an important contributing 
factor in AD is further substantiated by loss-of-function 
mutations seen in the filaggrin gene which is a major 
risk factor for development of AD (3, 7, 8). Filaggrin 
is a key protein in epidermal homeostasis and barrier 
integrity; and through its processing to free amino acids, 
it facilitates retention of water in the stratum corneum 
(SC) (natural moisturising factor) (3, 9). In conjunction 
with filaggrin, other proteins encoded by genes in the 
epidermal differentiation complex, including loricrin and 
involucrin, are indispensable elements of the epidermal 
barrier (3, 10). Skin alterations in AD are characterised 
by increased transepidermal water loss (TEWL) and a 
defective terminal keratinocyte differentiation entai-
ling reduced levels of filaggrin, involucrin and loricrin 
(11–13).
Loss-of-function mutations in the filaggrin gene are 
found in approximately one third of all AD patients and 
are considered responsible for the decreased skin barrier 
function, the increased TEWL and increased disease 
severity. Yet, all patients with AD display a reduced 
expression of filaggrin and also involucrin and loricrin. 
This phenomenon is explained in part by the impact of 
cytokines, e.g. interleukin (IL)-4, IL-13 and IL-25 that 
reduce the expression of barrier proteins (12–14). 
The cytokine IL-33 is a member of the IL-1-family. 
IL-33 is constitutively expressed in healthy skin and is 
upregulated in skin of AD patients and in AD-like lesions 
in mice (15–18). Furthermore, we recently found elevated 
IL-33 serum levels in children with AD (19, 20). IL-33 is 
classified as an alarmin due to the passive release upon 
cellular stress like allergen stimulation, scratching or 
non-apoptotic cell death, though these mechanism are 
still to be fully elucidated (16, 21, 22). It displays Th2 
immunomodulatory effects by inducing IL-5 and IL-13. 
It also displays a Th1 response via upregulation of IFN-γ 
(23). Keratinocytes produce IL-33 and also express its 
receptor complex consisting of ST2 and IL-1RAcP on 
their surface (16, 24). Moreover, IL-33 appears to exert 
receptor-independent transcriptional effects in the nu-
cleus of epithelial cells (25), thereby operating as a dual-
function immune mediator similarly to high-mobility 
group box 1 (HMGB1) (26). HMGB1 is localised in 
the nucleus in almost all cells and is rapidly mobilised 
to other sites within the cell, and into the extracellular 
space in response to a variety of stimuli (26, 27). Through 
RAGE and TLR4 signalling, HMGB1 mediates immune 
responses in non-infectious inflammation and shows 
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upregulation in the skin and serum of AD patients (28, 
29). HMGB1 sustains a long-term inflammatory state 
under stress similar to IL-33 by activating both kerati-
nocytes and a range of immune-competent cells (e.g., 
macro phages, monocytes and dendritic cells) which, 
in turn, form a positive feedback loop that causes the 
release of additional cytokines and chemokines (30–33). 
Although we have in-depth understanding of the 
systemic actions of IL-33 and HMGB1, little is known 
about their direct effects on skin barrier integrity and ho-
meostasis. In the present report, we investigate the impact 
of IL-33 and HMGB1 on primary human keratinocyte 
monolayer cultures and two different three-dimensional 
(3D) skin models. Our results demonstrate that HMGB1, 
and to a lesser extent IL-33, impair the gene transcrip-
tion and protein expression of a range of pivotal barrier 
and epidermal differentiation proteins. Moreover, they 
reduce the epidermal growth and thereby hamper the 
formation of a normal, fully stratified epidermis. These 
results indicate that HMGB1 and IL-33 may impair skin 
barrier function and that they may be new targets in the 
intraepidermal pathophysiology of AD.
MATERIALS AND METHODS
Primary human keratinocyte monolayer culture
Primary human keratinocytes were collected and cultured as 
described previously (34). All keratinocyte monolayer cultures 
(KMCs) and stimulations were performed in duplicate. For the 
analysis of IL-33 and HMGB1 synthesis, primary keratinocytes 
(n = 4) were grown to about 60% confluency, stimulated with 
IFN-γ (5 ng/ml, #285-IF, R&D Systems), IL-25 (10 ng/ml or 100 
ng/ml, #1258-IL, R&D Systems, Oxon, UK) or combinations of 
IFN-γ (5 ng/ml) and IL-25 (10 ng/ml or 100 ng/ml) for 24 h and 
collected in a lysis buffer for protein analysis. 
For the evaluation of filaggrin, loricrin, involucrin, hornerin, 
SPINK5 and matriptase mRNA levels, cells (n = 5) cultured in 
growth medium supplemented with 1.3 mM calcium (Ca) to 
increase differentiation were stimulated for 4 days at 70-80% 
confluency with recombinant human IL-25 (10 or 100 ng/ml), 
IL-33 (2, 10 or 100 ng/ml, #3625-IL, R&D Systems),) or dis-
ulphide HMGB1 (100 μM, #HM-121, HMGBiotech, Milano, 
Italy). After 48 h, the medium supplemented with cytokine was 
refreshed. The cells were collected on day 4, washed in ice-cold 
phosphate-buffered saline (PBS) and total RNA was isolated using 
the SV Total RNA Isolation System (Promega, Madison, USA) as 
previously described (35).
Western blot analysis of IL-33 and HMGB1 synthesis in kerati-
nocytes was performed as previously described (36). The following 
antibodies were used for evaluation of the protein expression: 
polyclonal goat anti-IL-33 (#AF3625; R&D Systems), polyclonal 
rabbit anti-HMGB1 (#ab18256, Abcam, Cambridge, UK) and hor-
seradish peroxidase-conjugated mouse anti-human β-actin (Clone 
c4; Santa Cruz Biotechnology, Dallas, USA). Primary antibodies 
were visualised using horseradish peroxidase-conjugated polyclo-
nal antibodies (p0449; DAKO, Glostrup, Denmark), (#7074, Cell 
Signalling Technology) and (p0447; DAKO). All samples were 
analysed in duplicate.
For RT-qPCR analysis, cDNA synthesis was performed using 
TaqMan reverse transcription reagents (Applied Biosystems, Walt-
ham, USA). RPLP0 (Ribosomal protein, large, P0) was used as 
reference gene. PCR master mix and primers and probes for filag-
grin, involucrin, loricrin, hornerin, matriptase, SPINK5 and RPLP0 
were all commercially available (Taqman Master Mix #4369016, 
Taqman IDs: Hs00856927_g1, Hs00846307_s1, Hs01894962_s1, 
Hs02340614_m1, Hs01058386_m1, Hs00928575_m1 and 
Hs99999902_m1; all from Applied Biosystems). The probe was 
a FAM-labelled MGB probe with a non-fluorescent quencher. 
Each gene was run in triplicate on a StepOnePlus PCR system 
PCR platform (Applied Biosystems). The target gene expression 
level was normalised to the reference gene (RPLP0). The average 
of non-stimulated controls was set to 1, and the relative gene ex-
pression levels in comparison with the control were determined.
Human epidermal equivalent
Primary keratinocytes were acquired from skin explants after ab-
dominoplasty (n = 7). Isolation was done as described previously 
(37). Keratinocytes (1 × 105) were seeded onto polystyrene inserts 
(Thincert, Greiner bio-one, Kremsmünster, Austria) in prolifera-
tion medium (CnT-Prime, CellnTec, Bern, Switzerland). On day 
2, the medium was replaced by a differentiation medium (3D 
barrier, CellnTec, Bern, Switzerland) complemented with DMEM 
(Gibco, Waltham, USA). Human epidermal equivalents (HEEs) 
were exposed to the air-liquid interface on day 3 to stimulate dif-
ferentiation and stratification. The medium was refreshed every 
other day. HEEs were stimulated with IL-4 (50 ng/ml, #204-IL, 
R&D Systems), IL-33 (100 ng/ml) and disulphide HMGB1 (100 
μM) on day 8. After 48 h, the medium supplemented with cytokine 
was changed. The HEEs were harvested for subsequent analysis on 
day 11. All cultures were antibiotics-free and handled with aseptic 
techniques in accordance with recommendations (19).
HEEs were fixated in a 4% buffered formalin solution and 
processed for routine histology. Paraffin sections of 6 µm were 
stained with haematoxylin and eosin to assess histology, while 
immunohistochemistry with indirect immunoperoxidase technique 
using avidin-biotin complex enhancement (Vectastain Labora-
tories, Burlingame, USA) was prepared to analyse epidermal 
differentiation. Antibodies against filaggrin (1:200; NCL-FLG, 
Leica Biosystems, Nussloch, Germany), loricrin (1:2000; BabCO, 
Covance, Princeton, USA), involucrin (1:20; Mon 150, custom 
made), keratin 10 (1:100; DE-K10, Eurodiagnostics, Apeldoorn, 
The Netherlands), keratin 14 (1:50; DE-K14, Eurodiagnostics), 
late cornified envelope 2 (1:1000; pan-anti-LCE2, custom made) 
and Ki67 (1:50; MIB-1; DAKO) were used and detected with 
3-amino-9-ethylcarbazole (AEC). All immunohistochemical 
stainings were performed with a strict time protocol to avoid 
intra-analysis variance. Fixed software settings were used during 
histopathological imaging to ensure minimal slide-to-slide va-
riability. An experienced technician blindly evaluated epidermal 
thickness and the number of ki67-positive cell nuclei. 
RNA from duplicates was isolated in accordance with the 
manufacturer’s protocol (RLT buffer, QIAGEN, Valencia, USA). 
Likewise, cDNA synthesis and RT-qPCR analyses were perfor-
med according to the manufacturer’s recommendation (Biorad, 
Hercules, USA). Target gene expression was normalised to the 
expression of RPLP0, and relative expression levels were calcula-
ted by the ΔΔCt method (38). SYBR Green primer sequences are 
depicted in Table SI1.
Human skin equivalent
In-depth description of the development, culturing and handling 
human skin equivalent (HSE) is provided in detail in previous 
1https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-2552
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
307HMGB1 and IL-33 regulate skin barrier proteins
Acta Derm Venereol 2017
publications (39, 40). HSEs (n = 6) were stimulated on day 8 with 
IL-4 (50 ng/ml), IL-33 (100 ng/ml), disulphide HMGB1 (100 μM) 
or left unhampered. On day 10, the medium supplemented with 
cytokine was changed. The HSEs were harvested on day 11. Tissue 
fixation, processing for HE staining, RNA extraction and RT-qPCR 
analysis were performed similarly to the HEE procedures after 
dispase-facilitated isolation of epidermis (39). 
Statistical analysis
The distribution of dependent data was assessed by histograms 
and Q-Q plots, which were supported by skewness and kurtosis 
tests for normality. Data that passed the normality test were 
analysed with unpaired t-test, paired t-test or one-way ANOVA, 
as appropriate. p-values < 0.05 were considered significant 
(*p < 0.05, **p < 0.01, ***p < 0.001). Statistics were performed 
using STATA version 12.0 (StataCorp, College Station, USA) 
Graphs were prepared in GraphPad Prism version 6 (GraphPad 
software, La Jolla, USA).
RESULTS
IL-33 and HMGB1 protein levels in keratinocyte 
monolayer cultures
Our study revealed a significant relative increase in the 
IL-33 protein level when KCs were stimulated with 
IFN-γ compared with unstimulated controls. However, 
co-stimulation with IL-25 had no significant additive 
effect; nor did IL-25 alone affect IL-33 production (Fig. 
1a, b). Studies of HMGB1 protein levels revealed only 
non-significant changes (Fig. 1, d).
mRNA expression profiles in keratinocyte monolayer 
cultures
IL-33 was tested in a dose-response study with 2, 20 and 
100 ng/ml. This test revealed a significant concentration-
dependent downregulation of involucrin (p = 0.016), 
while the other targets were non-significant (data not 
shown). HMGB1 showed non-significant changes in a 
comparison time-response study (24 vs. 96 h) (data not 
shown).
KMCs were hence stimulated for 96 h with IL-25 (100 
ng/ml), IL-33 (100 ng/ml) and HMGB1 (100 mM) which 
revealed a significant downregulation of filaggrin mRNA 
and involucrin mRNA and a non-significant regulation of 
loricrin, SPINK5 and matriptase mRNA compared with 
the relevant controls+Ca (Fig. 2). Controls without added 
Fig. 1. Interleukin (IL)-33 and high-mobility group box 1 (HMGB1) protein levels in keratinocytes stimulated with interferon (IFN)-γ 
and/or IL-25 (n = 4). (a) Densitometric band analysis of the Western blots showed significant IL-33 upregulation in all IFN-γ stimulations when 
compared with unstimulated control. (b) Representative IL-33 Western blots. (c) Quantified HMGB1 protein levels displayed no significant alterations. 
(d) Representative HMGB1 Western blots. Graphs show the relative (to unstimulated control) mean + standard deviation of measured protein levels. 
*p < 0.05 compared with control.  
Fig. 2. mRNA expression profiles in keratinocyte monolayer cultures 
measured by quantitative RT-PCR (n = 5). Filaggrin and involucrin mRNA 
levels were significantly downregulated following addition of interleukin 
(IL)-33 or high-mobility group box 1 (HMGB1). Graphs show the relative (to 
unstimulated control (-Ca)) mean + standard deviation (SD) of measured 
mRNA levels. *p < 0.05, **p <  0.01 compared with control+calcium (+Ca)).
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Ca showed significantly lower mRNA levels of filaggrin, 
involucrin and SPINK5 than controls with added Ca. 
mRNA expression profiles in human epidermal equivalents
Knowing that IL-33 and HMGB1 downregulated filag-
grin and involucrin in KMCs, we wanted to interrogate 
the same hypothesis in an organotypic human epidermis 
model. We included the archetypical Th2 cytokine IL-4 
as a positive control. Compared with the KMC studies, 
we excluded SPINK5 and matriptase due to an only 
modest sign of regulation from target cytokines, and 
included a wide range of other epidermal differentia-
tion genes. 
Our studies in HEEs revealed that stimulation with 
HMGB1 or IL-4 significantly downregulated the mRNA 
expression of filaggrin, involucrin, loricrin, LCE2A and 
KLK5. Furthermore, we found that IL-4 mediated a 
significant downregulation on the majority of additio-
nal targets (Table I). Most interestingly was the strong 
downregulation of residual structural protein genes, of 
kallikrein 5 and 7 and the highly significant upregula-
tion of IL-33. Besides LCE2A mRNA, IL-33 produced 
no significant regulation of any of the examined dif-
ferentiation genes, which is in contrast to the results 
obtained in the KMCs (Table I). Details on mRNA 
expression in individual genes are presented Fig. S11.
mRNA expression profiles in human skin equivalents
Concentrations and gene targets identical to those used 
in the HEE experiments were applied in the HSE study 
(Table I). HMGB1 produced downregulations paralleling 
those in the HEE model, in addition to hornerin, K10, and 
IL-18, and, interestingly, an increase in the IL-33 mRNA 
expression. Among other gene targets, IL-4 showed a 
consistent downregulation of all structural protein genes 
apart from loricrin. Similarly to the HEE analysis, a very 
significant upregulation of IL-33 mRNA was observed. 
IL-33 stimulation showed no significant regulation in the 
HSE model. Details on mRNA expression in individual 
genes are presented in Fig. S21.
Histology and immunohistochemistry in human 
epidermal equivalents
As PCR analysis suggested a potential impact of the tar-
get cytokines on cell proliferation and differentiation, we 
consequently performed HE and Ki67 stainings to eva-
luate HEE growth parameters, and Ki67-positive nuclei. 
Table I. mRNA expression profiles in human epidermal equivalents (HEE) (n = 7) and human skin equivalents (HSE) (n = 6)
HUGO gene symbol
FLG IVL LOR HRNR LCE2A KRT10 KRT14 FLG2 TLR4 CA2 KLK5 KLK7 IL-33 IL-18 IL1RL1 CCL26
HEE
IL-33 (100 ng/ml) – – – – â* – – – – – – – – – – –
HMGB1 (100 μM) â* â* â* – – – – – – – â* – – – – –
IL-4 (50 ng/ml) â*** â*** â** â* â*** â** â* â* – á*** á** â*** á*** â*** â** á*
HSE
IL-33 (100 ng/ml) – – – – – – – – – – – – – – – –
HMGB1 (100 μM) â** â** â** â** â** â** – – – – – – á** â* – –
IL-4 (50 ng/ml) â* â** – â* â* â* â* â* – – â* – á*** – á*** á*
*p < 0.05, **p < 0.01, ***p < 0.001 compared with control.
IL: interleukin; HUGO; HUman Genome Organisation; HMBG1: high mobility group box 1 protein; FLG: filaggrin; IVL: involucrin; LOR: loricrin; HRNR: hornerin; LCE2A: 
late cornified envelope 2A; KRT: keratin; TLR4: toll-like receptor 4; CA2: carbonic anhydrase II; KLK: kallikrein; IL1RL1: interleukin-1 receptor-like 1 (ST2); CCL26: 
chemokine (C-C motif) ligand 26; –non-significant regulation; áupregulation; âdownregulation.
Fig. 3. Human epidermal equivalents (HEE) display significant morphological changes upon IL (interleukin)-33 (100 ng/ml), high mobility 
group box 1 protein (HMGB1) (100 μM) and IL-4 (50 ng/ml) stimulation (n = 7). (a) The total epidermal thickness of the HEEs was significantly 
reduced in all stimulations. (b) IL-33 and HMGB1 significantly reduced the thickness of nucleated epidermal layers (NEL) (total epidermal thickness 
without the stratum corneum (SC). (c) HMGB1 and IL-4 significantly reduced the thickness of SC. Graphs display the mean + standard deviation (SD) 
of measured thickness. *p < 0.05, ***p < 0.001 compared with control.
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The total epidermal thickness of the HEEs was signifi-
cantly reduced in all stimulations (Fig. 3a). The thickness 
of the nucleated epidermal layers (NEL, total epidermal 
thickness without the SC) was reduced by IL-33 and 
HMGB1 stimulation, while the isolated SC thickness was 
significantly reduced by HMGB1 and IL-4 (Fig. 3b, c). 
The Ki67 analysis revealed a significant increase in the 
amount of Ki67-positive nuclei in all 3 stimulations (Fig. 
4). Fig S31 displays representative Ki67 and HE stainings. 
The protein expression of filaggrin in the upper epi-
dermis was distinctly diminished by HMGB1 and IL-4 
stimulation, while the supplement of IL-33 exhibited 
no apparent changes (Fig. 5). Involucrin staining was 
markedly decreased by IL-4, while HMGB1 produced 
a minor reduction and IL-33 no evident regulation (Fig. 
5). HMGB1 and IL-4 stimulation reduced the protein 
expression of loricrin; conversely, IL-33 stimulation 
increased the expression (Fig. 5). Despite downregula-
tion of LCE2A mRNA by all stimulations, immunohi-
stochemical staining did not support a corresponding 
reduction of protein expression, which may, in part, be 
explained by the difficulty of LCE2 immunohistochemi-
cal interpretation (Fig S41). IL-4 stimulation resulted in 
a clear reduction of K10 expression in the HEE model, 
whereas other K10 and K14 stainings were inconclusive 
compared with unstimulated controls (Fig. S41).
Histology and immunohistochemistry in human skin 
equivalents
HSE growth and differentiation were validated from HE 
staining presented in the online supplement (Fig. S51). 
Immunohistochemical stainings of HSEs were of little 
value because they displayed lesser upper epidermal dif-
ferentiation than HEEs which made the staining weaker 
and challenging to interpret (stainings not shown).
DISCUSSION
AD is characterised by a dysregulation of several cy-
tokines, and it has been suggested that these cytokines 
participate in disease pathophysiology (41, 42). Two of 
the effector cytokines possibly implicated in AD are the 
”alarmins” IL-33 and HMGB1. Other well-described 
cytokines, including IL-4, IL-13 and IL-25 (12-14, 16, 
28), may also be implicated. Here, we demonstrate for 
the first time that HMGB1 and IL-33 downregulate 
Fig. 4. Ki67-positive nuclei cell count in human epidermis equivalents 
is increased following interleukin (IL)-33, high mobility group box 
1 protein (HMGB1) or IL-4 stimulation (n = 7). IL-33 (100 ng/ml), 
HMGB1 (100 μM) and IL-4 (50 ng/ml) all produced a significant increase 
in the quantity of Ki67-positive nuclei. The graph displays the mean + 
standard deviation (SD) of Ki67-positive nuclei cell count. **p < 0.01, 
***p < 0.001 compared with control.
Fig. 5. The protein expression of filaggrin, involucrin and loricrin in the upper epidermis of human epidermis equivalents (HEE) is 
significantly regulated by interleukin (IL)-33, high mobility group box 1 protein (HMGB1) or IL-4 stimulation (n =  7). Representative 
immunohistochemical stainings of filaggrin, involucrin and loricrin upon IL-33 (100 ng/ml), HMGB1 (100 μM) or IL-4 (50 ng/ml) stimulation. The protein 
expression of filaggrin in the upper epidermis was distinctly diminished by HMGB1 and IL-4 stimulation. Involucrin staining was markedly decreased by 
IL-4, while HMGB1 produced a minor reduction. HMGB1 and IL-4 stimulation reduced the protein expression of loricrin; conversely, IL-33 stimulation 
increased the expression. Scale bar = 100 μm.
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transcription of genes from members of the epidermal 
differentiation complex. Furthermore, HMGB1 downre-
gulates the expression of several of the encoded proteins 
in the upper epidermis. Finally, we show that IL-33 and 
HMGB1 stimulation ultimately leads to impaired epi-
dermal growth and maturation. While HMGB1 shows 
uniform effects across 3 keratinocyte models, the impact 
of IL-33 is less pronounced. 
The inflammatory response mediated by HMGB1 is 
well characterised across a broad palette of cells and 
tissues (26). However, the role of HMGB1 in skin bar-
rier homeostasis and AD is poorly elucidated. HMGB1 
expression is chronically augmented during various types 
of skin inflammation, including AD (28, 29, 43–46). Our 
results give us reason to believe that constant HMGB1 
stimulation of keratinocytes within AD lesions can im-
pair natural barrier formation. Keeping in mind that the 
HMGB1 concentrations used in our study could enhance 
any effects compared with the pathophysiological situa-
tion, we show that HMGB1 heavily impacts the gene 
products of pivotal skin barrier differentiation genes, e.g. 
filaggrin, involucrin and loricrin. Consequently, HMGB1 
has deleterious effects on protein expression, epidermal 
growth and SC formation. This is in line with the effects 
of HMGB1 in lung and intestinal endothelia cells where 
HMGB1 gives rise to cytoskeletal rearrangement and 
barrier disruption (47, 48). We show an upregulation of 
Ki67 in the basal cell layer in HMGB1-stimulated cells 
that does not, as would be expected, result in increased 
epidermal growth and barrier maturation; in fact, we 
observe the opposite. These results are in concert with 
previous in vitro studies of HMGB1 as increased Ki67 
expression and cell proliferation of adult and embryonic 
mesoangioblasts disrupt the barrier function of endothe-
lial monolayers (49). Whether the impact of HMGB1 in 
the AD in vivo setting might mimic that seen in psoriasis 
need further exploration (45). 
IL-4 and HMGB1 experiments revealed a recurrent 
downregulation of kallikrein 5 mRNA. This regulation 
may hint at a meaningful counter response to the dete-
rioration of skin barrier formation as it is recognised that 
increased levels and activity of kallikrein 5 are important 
to the development and maintenance of AD. However, 
these possible dual functions need further study (50, 51). 
Additionally, in the 3D models HMGB1, in union with 
IL-4 showed a highly significant upregulation of the 
IL-33 mRNA product that parallels results reported in 
studies of other epithelial cells (52). This could indicate 
the existence of a damaging feedback loop enhancing 
any IL-33 properties, e.g systemic Th2 skewing TSLP 
and IL-13 upregulation in the skin, augmenting ongoing 
immunomodulation, diminishing barrier function and 
possibly reducing the effect of topical glucocorticosteroid 
treatment in AD patients (23, 53–56). 
IL-33 is reported to be elevated in both the blood 
and epidermis of AD patients (16, 17, 20). Our study 
verified the IL-33 production from keratinocytes under 
IFN-γ exposure. It also revealed an IL-33 upregulation 
after HMGB1 or IL-4 stimulation, and it disclosed a 
downregulation of filaggrin and involucrin mRNA in 
the KMCs upon IL-33 stimulation, although no regula-
tion was observed in either of the 3D models. These 
findings are partly in line with those of a previous study 
investigating similar causality (57). Seltmann et al. sho-
wed significant downregulation of filaggrin mRNA in 
lesional AD keratinocytes upon IL-33 stimulation. Still, 
they did not reproduce these results in normal human 
KMCs, AD skin biopsies or in a HEE model, data mir-
rored in our study. Lastly, and in contrast to our results, 
they reported a reduction in filaggrin protein expression 
by IL-33 evaluated through IHC staining of HEEs. The 
fact that we disclosed no effect of IL-33 on isolated SC 
thickness support our mRNA data, as neither of the eight 
gene targets representing the bulk mass of protein in the 
SC, was significantly regulated in either the HEE- or 
HSE mRNA profile. Together these findings give little 
reason to believe that IL-33 heavily impacts structural 
skin barrier protein expression and translation. However, 
the question remains unanswered whether IL-33 does, 
in fact, negatively impact production and maturation of 
filaggrin, involucrin and other structural barrier proteins. 
Our studies of HEE thickness support the evidence of an 
intraepidermal role of IL-33. We show a clear reduction 
of epidermal growth upon IL-33 stimulation despite 
an increased Ki67-positive cell count. This is possibly 
due to mechanisms mimicking those of HMGB1 where 
significant upregulation of Ki67 and cell proliferation do 
not translate into increased growth, but instead hamper 
epidermal development (49). This causality is further 
supported by the increased production of IL-33 from 
lung epithelial cells causing a reduced alveolar diffusion 
capacity and aggravation of chronic obstructive lung 
disease (58). 
Several papers describe the downregulatory effects 
of IL-4/IL-13 concerning keratinocyte proliferation, 
differentiation and filaggrin expression (12, 13, 57, 
59–61). Our present report offers a consolidation of 
the isolated impact of IL-4 on filaggrin, involucrin and 
loricrin gene and protein expression. Additionally, it is 
also the first study exploring the effect of IL-4 in HEEs 
supported by two additional models; and it furthermore 
shows impaired HEE growth and SC formation, thereby 
accentuating the prospect of the ongoing studies of AD 
patients treated with dupilumab, a fully human mono-
clonal antibody that blocks the IL-4 receptor subunit 
IL-4Rα, hence modulates signalling of both the IL-4 and 
IL-13 pathway (62, 63).
In the present study, we provide a triple in vitro study 
of the impact of HMGB1, IL-33 and IL-4 on the most 
pivotal epidermal differentiation genes, the protein 
expression in a HEE model and the evaluation of HEE 
growth and SC formation. Furthermore, we report a 
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consistent and convincing reduction of hallmark skin 
barrier gene and protein products upon stimulation 
with HMGB1 and IL-4. We speculate that HMGB1 has 
primary regulatory effects on keratinocyte homeostasis 
and could be a major target for future research into bar-
rier dysfunction in AD. IL-33 has only discrete gene 
and protein regulatory effects; however, its capacity to 
decelerate normal epidermal growth might turn out to be 
an important part of the negative feedback loop of the 
intraepidermal pathophysiology of AD.
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